Nothing Special   »   [go: up one dir, main page]
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Wnt signaling in B-cell neoplasia

Oncogene volume 22, pages 1536–1545 (2003)Cite this article

Abstract

Wnts comprise a family of secreted proteins that interact with receptors consisting of a Frizzled (Fz) family member alone or complexed with LDL receptor-related proteins (LRP5/6). Wnt signaling plays a crucial role in both development and differentiation, and activation of a ‘canonical’ Wnt pathway resulting in β-catenin stabilization is associated with several types of human cancers. To date, little is known about potential Wnt signaling in mature lymphocytes or lymphoid neoplasia. Herein, we have analysed Wnt signaling in mature B cells (lymphomas) and plasma cells (multiple myeloma). Both Fz and LRP5/6 mRNAs were expressed in myeloma lines, but LRP5/6 were not observed in lymphomas. In myelomas, a canonical Wnt signaling pathway was activated following treatment with Wnt-3a as assessed by accumulation of β-catenin, but β-catenin levels actually decreased in lymphoma cells. Wnt-3a treatment further led to striking morphological changes in myeloma cells accompanied by rearrangement of the actin cytoskeleton. Morphological changes were associated with a second Wnt pathway dependent on Rho activation. These results suggest that Wnt responsiveness is a stage-specific phenomenon in B-cell development and that the morphological changes associated with Wnt signaling may play a role in the motility and metastatic potential of myeloma cells.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Bataille R, Chappard D and Klein B . (1992). Hematol. Oncol. Clin. North Am., 6, 285–295.

  • Bergui L, Schena M, Gaidano G, Riva M and Caligaris-Cappio F . (1989). J. Exp. Med., 170, 613–618.

  • Brandon C, Eisenberg LM and Eisenberg CA . (2000). Blood, 96, 4132–4141.

  • Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N and Klein B . (2000). Br. J. Haematol., 111, 626–634.

  • Ge NL and Rudikoff S . (2000). Blood, 96, 4091–4095.

  • Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GCM, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, Paepe AD, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, Boogaard M, Hul WV, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR and Warman ML . (2001). Cell, 107, 513–523.

  • Habas R, Kato Y and He X . (2001). Cell, 107, 843–854.

  • Hilbert DM, Kopf M, Mock BA, Kohler G and Rudikoff S . (1995). J. Exp. Med., 182, 243–248.

  • Ioannidis V, Beermann F, Clevers H and Held W . (2001). Nat. Immunol., 2, 691–697.

  • Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M and Narumiya S . (2000). Mol. Pharm., 57, 976–983.

  • Korinek V, Barker N, Morin P, van Wichen D, de Weger R, Kinzler K, Vogelstein B and Clevers H . (1997). Science, 275, 1784–1787.

  • Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P and Poli V . (1997). Am. J. Pathol., 151, 689–696.

  • Lee JS, Ishimoto A and Yanagawa S . (1999). J. Biol. Chem., 274, 21464–21470.

  • Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C and Manning SP . (2002). Am. J. Hum. Genet., 70, 11–19.

  • Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF and Klein B . (1995). Blood, 86, 3123–3131.

  • Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A and Niehrs C . (2001). Nature, 411, 321–325.

  • McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR and Murre C . (1999). Proc. Natl. Acad. Sci. USA, 96, 11464–11469.

  • Miller J, Hocking A, Brown J and Moon R . (1999). Oncogene, 18, 7860–7872.

  • Niesvizky R and Warrell RJ . (1997). Cancer Invest., 15, 85–90.

  • Oosterwegel M, van de Wetering M, Timmerman J, Kruisbeek A, Destree O and Meijlink F . (1993). Development, 118, 439–448.

  • Peifer M and Polakis P . (2000). Science, 287, 1606–1609.

  • Pinson KI, Brennan J, Monkley S, Avery BJ and Skarnes WC . (2000). Nature, 407, 535–538.

  • Polakis P . (2000). Genes Dev., 14, 1837–1851.

  • Qiang Y, Kopantzev E and Rudikoff S . (2002). Blood, 99, 4138–4146.

  • Ren X, Kiosses W and Schwartz M . (1999). EMBO J., 18, 578–585.

  • Reya T, O’Riordan M, Okamura R, Devaney E, Willert K, Nusse R and Grosschedl R . (2000). Immunity, 13, 15–24.

  • Semenov MV and Snyder M . (1997). Genomics, 42, 302–310.

  • Semenov M, Tamai K, Brott B, Kuhl M, Sokol S and He X . (2001). Curr. Biol., 11, 951–961.

  • Shibamoto S, Higano K, Takada R, Ito F, Takeichi M and Takada S . (1998). Genes Cells, 3, 659–670

  • Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP and He X . (2000). Nature, 407, 530–535.

  • Uren A, Reichsman F, Anest V, Taylor WG, Muraiso K, Bottaro DP, Cumberledge S and Rubin JS . (2000). J. Biol. Chem., 275, 4374–4382.

  • Van de Wetering M, Castrop J, Korinek V and Clevers H . (1996). Mol. Cell Biol., 16, 745–752.

  • Wehrli M, Dougan ST, Caldwell K, O’Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A and DiNardo S . (2000). Nature, 407, 527–530.

  • Winter C, Wang B, Ballew A, Royou A, Karess R, Axelrod J and Luo L . (2001). Cell, 105, 81–91

  • Wodarz A and Nusse R . (1998). Annu. Rev. Cell Dev. Biol., 14, 59–88.

  • Yamane T, Kunisada T, Tsukamoto H, Yamazaki H, Niwa H, Takada S and Hayashi SI . (2001). J. Immunol., 167, 765–772.

  • Yanagawa S, van Leeuwen F, Wodarz A, Klingensmith J and Nusse R . (1995). Genes Dev., 9, 1087–1097.

  • Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R and Klein B . (1994). Blood, 83, 3654–3663.

  • Zhurinsky J, Shtutman M and Ben-Ze’ev A . (2000). J. Cell Sci., 113, 3127–3139.

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, 20892, MD, USA

    Ya-Wei Qiang, Yoshimi Endo, Jeffrey S Rubin & Stuart Rudikoff

Authors
  1. Ya-Wei Qiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshimi Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey S Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stuart Rudikoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart Rudikoff.

Additional information

This article is a United States Government Work Paper as defined by the US Copyright Act

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qiang, YW., Endo, Y., Rubin, J. et al. Wnt signaling in B-cell neoplasia. Oncogene 22, 1536–1545 (2003). https://doi.org/10.1038/sj.onc.1206239

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206239

Keywords

This article is cited by

Search

Advanced search

Quick links